BRPI0717357A2 - Compostos inibidores de mtp de ácido tetra-hidro-naftaleno-1-carboxílico substituído com piperidina ou piperazina - Google Patents

Compostos inibidores de mtp de ácido tetra-hidro-naftaleno-1-carboxílico substituído com piperidina ou piperazina

Info

Publication number
BRPI0717357A2
BRPI0717357A2 BRPI0717357-1A2A BRPI0717357A BRPI0717357A2 BR PI0717357 A2 BRPI0717357 A2 BR PI0717357A2 BR PI0717357 A BRPI0717357 A BR PI0717357A BR PI0717357 A2 BRPI0717357 A2 BR PI0717357A2
Authority
BR
Brazil
Prior art keywords
tetrahydro
piperazine
piperidine
naphthalene
replaced
Prior art date
Application number
BRPI0717357-1A2A
Other languages
English (en)
Inventor
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Marcel Viellevoye
Leo Jacobus Jozef Backx
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0717357A2 publication Critical patent/BRPI0717357A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0717357-1A2A 2006-10-24 2007-10-22 Compostos inibidores de mtp de ácido tetra-hidro-naftaleno-1-carboxílico substituído com piperidina ou piperazina BRPI0717357A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
BRPI0717357A2 true BRPI0717357A2 (pt) 2013-10-22

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717357-1A2A BRPI0717357A2 (pt) 2006-10-24 2007-10-22 Compostos inibidores de mtp de ácido tetra-hidro-naftaleno-1-carboxílico substituído com piperidina ou piperazina

Country Status (27)

Country Link
US (1) US8114880B2 (pt)
EP (1) EP2076494B1 (pt)
JP (1) JP5506085B2 (pt)
KR (1) KR101415536B1 (pt)
CN (1) CN101528695B (pt)
AR (1) AR063517A1 (pt)
AT (1) ATE475648T1 (pt)
AU (1) AU2007310925B2 (pt)
BR (1) BRPI0717357A2 (pt)
CA (1) CA2664141C (pt)
CL (1) CL2007003042A1 (pt)
CY (1) CY1111010T1 (pt)
DE (1) DE602007008124D1 (pt)
DK (1) DK2076494T3 (pt)
EA (1) EA016311B1 (pt)
IL (1) IL198332A (pt)
JO (1) JO2653B1 (pt)
MX (1) MX2009004386A (pt)
NO (1) NO20092005L (pt)
NZ (1) NZ575615A (pt)
PL (1) PL2076494T3 (pt)
PT (1) PT2076494E (pt)
SI (1) SI2076494T1 (pt)
TW (1) TWI396688B (pt)
UA (1) UA99109C2 (pt)
WO (1) WO2008049806A1 (pt)
ZA (1) ZA200902822B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EA017376B1 (ru) * 2006-10-24 2012-12-28 Янссен Фармацевтика Нв Производные тетрагидронафталин-1-карбоновой кислоты, ингибирующие мтр
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
HRP20171587T1 (hr) * 2010-10-18 2017-12-01 Cerenis Therapeutics Holding Sa Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
US11827586B2 (en) * 2018-05-15 2023-11-28 Asahi Kasei Kabushiki Kaisha Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
TR199901180T2 (xx) 1996-11-27 1999-08-23 Pfizer Inc. Apo B-Salg�lama/MTP inhibit�r amidler.
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
EA017376B1 (ru) 2006-10-24 2012-12-28 Янссен Фармацевтика Нв Производные тетрагидронафталин-1-карбоновой кислоты, ингибирующие мтр

Also Published As

Publication number Publication date
HK1136823A1 (en) 2010-07-09
CA2664141A1 (en) 2008-05-02
KR101415536B1 (ko) 2014-07-16
AU2007310925B2 (en) 2012-07-26
PL2076494T3 (pl) 2011-01-31
CA2664141C (en) 2015-04-28
JO2653B1 (en) 2012-06-17
TWI396688B (zh) 2013-05-21
IL198332A (en) 2012-08-30
CN101528695A (zh) 2009-09-09
KR20090075832A (ko) 2009-07-09
NO20092005L (no) 2009-06-04
NZ575615A (en) 2011-01-28
EA200970398A1 (ru) 2009-08-28
JP5506085B2 (ja) 2014-05-28
ATE475648T1 (de) 2010-08-15
AR063517A1 (es) 2009-01-28
EA016311B1 (ru) 2012-04-30
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
DE602007008124D1 (de) 2010-09-09
MX2009004386A (es) 2009-05-08
WO2008049806A1 (en) 2008-05-02
AU2007310925A1 (en) 2008-05-02
CN101528695B (zh) 2013-07-17
ZA200902822B (en) 2010-07-28
US8114880B2 (en) 2012-02-14
CL2007003042A1 (es) 2008-05-02
UA99109C2 (ru) 2012-07-25
DK2076494T3 (da) 2010-11-08
SI2076494T1 (sl) 2010-11-30
CY1111010T1 (el) 2015-06-11
IL198332A0 (en) 2010-02-17
EP2076494B1 (en) 2010-07-28
JP2010507615A (ja) 2010-03-11
TW200833680A (en) 2008-08-16
EP2076494A1 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
CY2022037I1 (el) Ιμιδαζοτριαζινες με ιμιδαζοπυριμιδινες ως αναστολεις κινασης
EP2051707A4 (en) Plasma kallikrein INHIBITORS
ATE488505T1 (de) Kinasehemmer auf hydantoinbasis
DK2610258T3 (da) Substituerede piperidindihydrothienopyrimidiner
BRPI0817644A2 (pt) Derivados de piperidina e piperazina
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2076494T3 (da) Piperidin- eller piperazinsubstituerede tetrahydro-naphthalen-1-carboxylsyre-mtp-inhiberende forbindelser
ATE506359T1 (de) Heteroaryl-substituierte piperidine
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI0812923A2 (pt) Derivados de piperidina/piperazina
BRPI0813331A2 (pt) Derivados de piperidina/piperazina
ATE510839T1 (de) Benzofuropyrimidinone als proteinkinase-hemmer
BRPI0719991A2 (pt) Derivados de di-hidropiridina úteis como inibidores de proteína cinase
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
EP1973889A4 (en) Cetp inhibitors
BRPI0817781A2 (pt) piperazino-diidroteinopirimidinas substituídas com heterociclo
DK3564240T3 (da) Piperidinmellemprodukter
NO20085127L (no) Leptomycinderivater
ATE510923T1 (de) Nukleinsäure
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2537 DE 20-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.